BiotechTube

rFVIIIFc

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hemophilia A With Inhibitors

Conditions

Hemophilia A With Inhibitors

Trial Timeline

Dec 8, 2017 → Feb 16, 2021

NCT ID
NCT03093480

About rFVIIIFc

rFVIIIFc is a approved stage product being developed by Swedish Orphan Biovitrum for Hemophilia A With Inhibitors. The current trial status is completed. This product is registered under clinical trial identifier NCT03093480. Target conditions include Hemophilia A With Inhibitors.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A With Inhibitors were approved

Approved (20) Terminated (3) Active (0)
✅EmicizumabRocheApproved
✅BenefixPfizerApproved
✅Nonacog alfaPfizerApproved
✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved
✅Recombinant Factor IX CoagulationPfizerApproved
✅Moroctocog alfa(AF-CC)PfizerApproved
✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03093480ApprovedCompleted
NCT02502149Phase 3Completed
NCT02234323Phase 3Completed

Competing Products

20 competing products in Hemophilia A With Inhibitors

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
40
EmicizumabChugai PharmaceuticalPhase 3
40
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
40
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
47
EmicizumabChugai PharmaceuticalPhase 3
47
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
40
EmicizumabRochePhase 3
40
HEMLIBRAJohnson & JohnsonPre-clinical
26
EmicizumabRochePhase 3
40
EmicizumabRocheApproved
47
EmicizumabRochePhase 3
44
SPK-8011QQRochePhase 1/2
39
NXT007RochePhase 1/2
39
Emicizumab InjectionRochePhase 2
35
Bypassing Agents + FVIII ReplacementRochePre-clinical
26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
35
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
26
Refacto AFPfizerPre-clinical
18
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
44
ReFacto AFPfizerPhase 3
40